HRP20080608T3 - Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors - Google Patents

Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors

Info

Publication number: HRP20080608T3
Authority: HR; Croatia
Prior art keywords: independently selected; optionally substituted; halogen; alkyl; co2h
Prior art date: 2004-08-12

Application number

HR20080608T

Other languages

English (en)

Croatian (hr)

Inventor

Paul Mathias John

Simon Millan David

Andrew Lewthwaite Russell

Phillips Christopher

Original Assignee

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-08-12

Filing date

2008-11-24

Publication date

2008-12-31

2004-08-12 Priority claimed from GB0418015A external-priority patent/GB0418015D0/en

2008-11-24 Application filed by Pfizer Inc. filed Critical Pfizer Inc.

2008-12-31 Publication of HRP20080608T3 publication Critical patent/HRP20080608T3/xx

Links

239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title 1
102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 title 1
108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 title 1
229910052736 halogen Inorganic materials 0.000 abstract 9
150000002367 halogens Chemical class 0.000 abstract 9
125000001424 substituent group Chemical group 0.000 abstract 9
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 8
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
125000003118 aryl group Chemical group 0.000 abstract 5
125000004093 cyano group Chemical group *C#N 0.000 abstract 4
125000001072 heteroaryl group Chemical group 0.000 abstract 4
125000000623 heterocyclic group Chemical group 0.000 abstract 4
125000001624 naphthyl group Chemical group 0.000 abstract 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
125000002619 bicyclic group Chemical group 0.000 abstract 3
125000004452 carbocyclyl group Chemical group 0.000 abstract 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
-1 CONR5R6 Chemical group 0.000 abstract 2
125000004432 carbon atom Chemical group C* 0.000 abstract 2
125000004122 cyclic group Chemical group 0.000 abstract 2
125000005842 heteroatom Chemical group 0.000 abstract 2
125000002950 monocyclic group Chemical group 0.000 abstract 2
125000002757 morpholinyl group Chemical group 0.000 abstract 2
125000004193 piperazinyl group Chemical group 0.000 abstract 2
125000003386 piperidinyl group Chemical group 0.000 abstract 2
125000000719 pyrrolidinyl group Chemical group 0.000 abstract 2
229920006395 saturated elastomer Polymers 0.000 abstract 2
125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
101100054666 Streptomyces halstedii sch3 gene Chemical group 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
125000004104 aryloxy group Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
125000005844 heterocyclyloxy group Chemical group 0.000 abstract 1
125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Neurology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Tropical Medicine & Parasitology (AREA)
Ophthalmology & Optometry (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Physical Education & Sports Medicine (AREA)
Psychology (AREA)
Reproductive Health (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)

HR20080608T 2004-08-12 2008-11-24 Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors HRP20080608T3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0418015A GB0418015D0 (en)	2004-08-12	2004-08-12	New compounds
US69155905P	2005-06-17	2005-06-17
PCT/IB2005/002574 WO2006018718A2 (en)	2004-08-12	2005-08-09	Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors

Publications (1)

Publication Number	Publication Date
HRP20080608T3 true HRP20080608T3 (en)	2008-12-31

Family

ID=35783420

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20080608T HRP20080608T3 (en)	2004-08-12	2008-11-24	Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors

Country Status (35)

Country	Link
US (2)	US7511057B2 (nl)
EP (1)	EP1778686B9 (nl)
JP (1)	JP4084836B2 (nl)
AP (1)	AP2326A (nl)
AR (1)	AR050692A1 (nl)
AT (1)	ATE412652T1 (nl)
AU (1)	AU2005273612B2 (nl)
BR (1)	BRPI0514255A (nl)
CA (1)	CA2576297C (nl)
CR (1)	CR8918A (nl)
CU (1)	CU23497A3 (nl)
CY (1)	CY1108788T1 (nl)
DE (1)	DE602005010714D1 (nl)
DK (1)	DK1778686T3 (nl)
EA (1)	EA012119B1 (nl)
EC (1)	ECSP077232A (nl)
ES (1)	ES2314690T3 (nl)
GE (1)	GEP20104973B (nl)
GT (1)	GT200500218A (nl)
HK (1)	HK1105536A1 (nl)
HN (1)	HN2005000418A (nl)
HR (1)	HRP20080608T3 (nl)
IL (1)	IL181047A (nl)
MA (1)	MA28798B1 (nl)
MX (1)	MX2007001759A (nl)
MY (1)	MY140021A (nl)
NL (1)	NL1029726C2 (nl)
NO (1)	NO339320B1 (nl)
NZ (1)	NZ552868A (nl)
PL (1)	PL1778686T3 (nl)
PT (1)	PT1778686E (nl)
SI (1)	SI1778686T1 (nl)
SV (1)	SV2006002193A (nl)
TN (1)	TNSN07050A1 (nl)
WO (1)	WO2006018718A2 (nl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7579360B2 (en) *	2005-06-09	2009-08-25	Bristol-Myers Squibb Company	Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7572807B2 (en) *	2005-06-09	2009-08-11	Bristol-Myers Squibb Company	Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
WO2007091152A1 (en) *	2006-02-09	2007-08-16	Pfizer Limited	Triazolopyridine compounds
JP5244369B2 (ja) *	2006-11-10	2013-07-24	富士フイルム株式会社	５−アミノピラゾール誘導体の製造方法、アゾ色素
EP1992344A1 (en)	2007-05-18	2008-11-19	Institut Curie	P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
US8119658B2 (en) *	2007-10-01	2012-02-21	Bristol-Myers Squibb Company	Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
ES2423991T3 (es) *	2008-02-04	2013-09-26	Pfizer Limited	Forma polimórfica de un derivado de [1,2,4]triazolo[4,3-a]piridina para el tratamiento de enfermedades inflamatorias
US8498729B2 (en)	2008-08-29	2013-07-30	Smp Logic Systems Llc	Manufacturing execution system for use in manufacturing baby formula
WO2010029167A2 (en) *	2008-09-12	2010-03-18	Universitätsklinikum Münster	Means and methods for evaluating a therapy with a p38 map kinase inhibitor
EP2398798A1 (en)	2009-02-17	2011-12-28	CHIESI FARMACEUTICI S.p.A.	Triazolopyridine derivatives as p38 map kinase inhibitors
GB0905955D0 (en)	2009-04-06	2009-05-20	Respivert Ltd	Novel compounds
WO2010141796A2 (en)	2009-06-05	2010-12-09	Cephalon, Inc.	PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES
GB201005589D0 (en)	2010-04-01	2010-05-19	Respivert Ltd	Novel compounds
JP5787977B2 (ja)	2010-04-08	2015-09-30	レスピバート・リミテツド	Ｐ３８ｍａｐキナーゼ阻害剤
WO2011158044A2 (en)	2010-06-17	2011-12-22	Respivert Limited	Respiratory formulations and compounds for use therein
US9416132B2 (en)	2011-07-21	2016-08-16	Tolero Pharmaceuticals, Inc.	Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
EP2578582A1 (en)	2011-10-03	2013-04-10	Respivert Limited	1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
EP2763984B1 (en)	2011-10-03	2016-04-20	Respivert Limited	1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 map kinase inhibitors
EP2788348B1 (en)	2011-12-09	2016-10-19	Chiesi Farmaceutici S.p.A.	Kinase inhibitors
RU2586333C1 (ru)	2011-12-09	2016-06-10	КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.	Производные 4-гидрокси-1,2,3,4-тетрагидронафталин-1-ил-мочевины и их применение в лечении, среди прочего, заболеваний дыхательного тракта
CA2858447C (en)	2011-12-09	2020-10-27	Monique Bodil Van Niel	Tryazolopyridine derivatives as kinase inhibitors
GB201214750D0 (en)	2012-08-17	2012-10-03	Respivert Ltd	Compounds
US20160016934A1 (en)	2013-03-14	2016-01-21	Respivert Limited	Kinase inhibitors
KR20160016973A (ko) *	2013-06-06	2016-02-15	키에시 파르마슈티시 엣스. 피. 에이.	P38 - map 키나아제 억제제로서 [1, 2, 4] 트리아졸로 [4, 3 - a] 피리딘의 유도체
GB201511382D0 (en)	2015-06-29	2015-08-12	Imp Innovations Ltd	Novel compounds and their use in therapy
WO2017151409A1 (en)	2016-02-29	2017-09-08	University Of Florida Research Foundation, Incorporated	Chemotherapeutic methods
AU2018346712B2 (en)	2017-10-05	2021-04-01	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
KR20210146290A (ko)	2019-02-12	2021-12-03	스미토모 다이니폰 파마 온콜로지, 인크.	헤테로시클릭 단백질 키나제 억제제를 포함하는 제제

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3050525A (en) *	1960-12-14	1962-08-21	John B Bicking	Certain derivatives of s-triazolo [4, 3-a]-pyridine
US3754887A (en) *	1969-05-05	1973-08-28	Du Pont	Ureidopyrazoles defoliants
US4183854A (en) *	1976-11-10	1980-01-15	John Wyeth & Brother Limited	Thiazole compound
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
JP2627348B2 (ja) *	1990-03-16	1997-07-02	セイコー電子工業株式会社	ラインサーマルプリンタ
JPH11503110A (ja)	1995-02-17	1999-03-23	スミスクライン・ビーチャム・コーポレイション	Ｉｌ−８受容体拮抗剤
GB9518953D0 (en)	1995-09-15	1995-11-15	Pfizer Ltd	Pharmaceutical formulations
EA004771B1 (ru)	1996-04-23	2004-08-26	Вертекс Фармасьютикалз Инкорпорейтед	Производные мочевины и их применение в качестве ингибиторов инозин-5`-монофосфат- дегидрогеназы
WO2000035296A1 (en)	1996-11-27	2000-06-22	Wm. Wrigley Jr. Company	Improved release of medicament active agents from a chewing gum coating
DE69720051T2 (de) *	1996-12-03	2003-09-04	Banyu Pharma Co Ltd	Harnstoffderivate
US6087381A (en)	1997-05-22	2000-07-11	G. D. Searle & Company	Pyrazole derivatives as p38 kinase inhibitors
BR9809451A (pt)	1997-05-22	2000-06-20	Searle & Co	Pirazóis substituìdos com 3(5)-heteroarila como inibidores de quinase p38.
ID22982A (id)	1997-05-22	1999-12-23	Searle & Co	PIRAZOL-PIRAZOL TERSUBSTITUSI SEBAGAI INHIBITOR KINASE p38
US6514977B1 (en) *	1997-05-22	2003-02-04	G.D. Searle & Company	Substituted pyrazoles as p38 kinase inhibitors
GB9711643D0 (en)	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
US6339099B1 (en) *	1997-06-20	2002-01-15	Dupont Pharmaceuticals Company	Guanidine mimics as factor Xa inhibitors
KR100571588B1 (ko)	1997-12-22	2006-04-17	바이엘 코포레이션	치환 헤테로시클릭 우레아를 이용한 ｒａｆ 키나제의 억제
CA2331878A1 (en)	1998-05-14	1999-11-18	G.D. Searle & Co.	1,5-diaryl substituted pyrazoles as p38 kinase inhibitors
AU8238298A (en)	1998-07-30	2000-02-21	Gulserene Dastur	Weather-proof furniture system mainly for outdoor use
US6350744B1 (en)	1998-11-20	2002-02-26	Merck & Co., Inc.	Compounds having cytokine inhibitory activity
US6469018B1 (en)	1999-01-08	2002-10-22	Smithkline Beecham Corporation	Compounds
UA73492C2 (en)	1999-01-19	2005-08-15		Aromatic heterocyclic compounds as antiinflammatory agents
JP2001247569A (ja)	1999-08-12	2001-09-11	Japan Tobacco Inc	ピロリジン誘導体又はピペリジン誘導体及びその医薬用途
US6387900B1 (en) *	1999-08-12	2002-05-14	Pharmacia & Upjohn S.P.A.	3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
US6525046B1 (en) *	2000-01-18	2003-02-25	Boehringer Ingelheim Pharmaceuticals, Inc.	Aromatic heterocyclic compounds as antiinflammatory agents
WO2001057038A1 (de) *	2000-02-01	2001-08-09	Basf Aktiengesellschaft	Heterozyklische verbindungen und deren anwendung als parp-inhibitoren
US7978329B2 (en)	2000-08-02	2011-07-12	Honeywell International Inc.	Portable scattering and fluorescence cytometer
ES2260415T3 (es) *	2001-03-09	2006-11-01	Pfizer Products Inc.	Triazolopiridinas como agentes antiimflamatorios.
EP1408950B1 (en)	2001-07-11	2007-04-25	Boehringer Ingelheim Pharmaceuticals Inc.	Methods of treating cytokine mediated diseases
US6924276B2 (en)	2001-09-10	2005-08-02	Warner-Lambert Company	Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
US6921762B2 (en) *	2001-11-16	2005-07-26	Amgen Inc.	Substituted indolizine-like compounds and methods of use
WO2003059891A1 (en)	2002-01-18	2003-07-24	Pharmacia Corporation	Substituted pyridazinones as inhibitors of p38
WO2003068223A1 (en)	2002-02-11	2003-08-21	Bayer Corporation	Aryl ureas with raf kinase and angiogenesis inhibiting activity
PL218749B1 (pl)	2002-02-14	2015-01-30	Pharmacia Corp	Pochodna pirydynonu oraz jej zastosowanie do wytwarzania leku
EP1495016A2 (en)	2002-04-09	2005-01-12	Astex Technology Limited	Heterocyclic compounds and their use as modulators of p38 map kinase
MXPA04011638A (es)	2002-06-05	2005-03-07	Pharmacia Corp	Derivados de pirazol como inhibidores de la quinasa p38.
US20060063782A1 (en)	2002-07-03	2006-03-23	Murray Christopher W	3-Hetero arylmethoxy ! pyridines and their analogues as p38 map kinase inhibitors
MXPA05008568A (es) *	2003-02-14	2005-11-04	Pfizer Prod Inc	Nuevos compuestos anti-inflamatorios triazolo-piridinas.
CL2004000366A1 (es) *	2003-02-26	2005-01-07	Pharmacia Corp Sa Organizada B	USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
US7135575B2 (en) *	2003-03-03	2006-11-14	Array Biopharma, Inc.	P38 inhibitors and methods of use thereof
WO2004078116A2 (en)	2003-03-03	2004-09-16	Array Biopharma, Inc.	P38 inhibitors and methods of use thereof
US7183287B2 (en)	2003-04-03	2007-02-27	Pharmacia Corporation	Substituted pyrimidinones
GB0320244D0 (en)	2003-05-06	2003-10-01	Aventis Pharma Inc	Pyrazoles as inhibitors of tumour necrosis factor

2005
- 2005-08-09 EA EA200700219A patent/EA012119B1/ru not_active IP Right Cessation
- 2005-08-09 DE DE602005010714T patent/DE602005010714D1/de active Active
- 2005-08-09 JP JP2007525382A patent/JP4084836B2/ja not_active Expired - Fee Related
- 2005-08-09 BR BRPI0514255-5A patent/BRPI0514255A/pt not_active IP Right Cessation
- 2005-08-09 AU AU2005273612A patent/AU2005273612B2/en not_active Ceased
- 2005-08-09 WO PCT/IB2005/002574 patent/WO2006018718A2/en active Application Filing
- 2005-08-09 SI SI200530498T patent/SI1778686T1/sl unknown
- 2005-08-09 PL PL05772546T patent/PL1778686T3/pl unknown
- 2005-08-09 ES ES05772546T patent/ES2314690T3/es active Active
- 2005-08-09 PT PT05772546T patent/PT1778686E/pt unknown
- 2005-08-09 EP EP05772546A patent/EP1778686B9/en active Active
- 2005-08-09 DK DK05772546T patent/DK1778686T3/da active
- 2005-08-09 AP AP2007003905A patent/AP2326A/xx active
- 2005-08-09 NZ NZ552868A patent/NZ552868A/en not_active IP Right Cessation
- 2005-08-09 AT AT05772546T patent/ATE412652T1/de active
- 2005-08-09 CA CA2576297A patent/CA2576297C/en not_active Expired - Fee Related
- 2005-08-09 GE GEAP20059863A patent/GEP20104973B/en unknown
- 2005-08-09 MX MX2007001759A patent/MX2007001759A/es active IP Right Grant
- 2005-08-10 HN HN2005000418A patent/HN2005000418A/es unknown
- 2005-08-10 US US11/201,823 patent/US7511057B2/en not_active Expired - Fee Related
- 2005-08-10 MY MYPI20053731A patent/MY140021A/en unknown
- 2005-08-11 AR ARP050103357A patent/AR050692A1/es unknown
- 2005-08-11 GT GT200500218A patent/GT200500218A/es unknown
- 2005-08-12 NL NL1029726A patent/NL1029726C2/nl not_active IP Right Cessation
- 2005-08-12 SV SV2005002193A patent/SV2006002193A/es unknown
2007
- 2007-01-29 IL IL181047A patent/IL181047A/en not_active IP Right Cessation
- 2007-02-08 CU CU20070042A patent/CU23497A3/es active IP Right Grant
- 2007-02-09 EC EC2007007232A patent/ECSP077232A/es unknown
- 2007-02-09 CR CR8918A patent/CR8918A/es unknown
- 2007-02-09 TN TNP2007000050A patent/TNSN07050A1/fr unknown
- 2007-02-12 MA MA29676A patent/MA28798B1/fr unknown
- 2007-03-07 NO NO20071242A patent/NO339320B1/no not_active IP Right Cessation
- 2007-10-04 HK HK07110750.2A patent/HK1105536A1/xx not_active IP Right Cessation
2008
- 2008-11-24 HR HR20080608T patent/HRP20080608T3/xx unknown
- 2008-12-01 CY CY20081101380T patent/CY1108788T1/el unknown
2009
- 2009-02-16 US US12/371,719 patent/US8076356B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
SI1778686T1 (sl)	2009-02-28
MA28798B1 (fr)	2007-08-01
HN2005000418A (es)	2009-12-07
US20090239899A1 (en)	2009-09-24
GT200500218A (es)	2006-03-21
NO339320B1 (no)	2016-11-28
PL1778686T3 (pl)	2009-04-30
PT1778686E (pt)	2008-12-26
JP4084836B2 (ja)	2008-04-30
EA012119B1 (ru)	2009-08-28
WO2006018718A2 (en)	2006-02-23
JP2008509901A (ja)	2008-04-03
CY1108788T1 (el)	2014-07-02
CR8918A (es)	2007-04-02
MY140021A (en)	2009-11-30
EP1778686B9 (en)	2009-07-08
HK1105536A1 (en)	2008-02-15
CA2576297A1 (en)	2006-02-23
US7511057B2 (en)	2009-03-31
IL181047A0 (en)	2007-07-04
IL181047A (en)	2011-06-30
NL1029726C2 (nl)	2007-08-14
TNSN07050A1 (fr)	2008-06-02
CA2576297C (en)	2011-01-25
NO20071242L (no)	2007-05-07
ES2314690T3 (es)	2009-03-16
AR050692A1 (es)	2006-11-15
AP2007003905A0 (en)	2007-02-28
MX2007001759A (es)	2007-04-20
EA200700219A1 (ru)	2007-08-31
AU2005273612B2 (en)	2010-10-14
DE602005010714D1 (de)	2008-12-11
US8076356B2 (en)	2011-12-13
SV2006002193A (es)	2006-03-15
GEP20104973B (en)	2010-04-26
ATE412652T1 (de)	2008-11-15
BRPI0514255A (pt)	2008-06-03
NL1029726A1 (nl)	2006-02-14
CU23497A3 (es)	2010-03-25
AP2326A (en)	2011-11-24
AU2005273612A1 (en)	2006-02-23
DK1778686T3 (da)	2009-01-12
NZ552868A (en)	2009-07-31
ECSP077232A (es)	2007-03-29
EP1778686B1 (en)	2008-10-29
EP1778686A2 (en)	2007-05-02
WO2006018718A3 (en)	2006-05-04
US20060035922A1 (en)	2006-02-16

Publication	Publication Date	Title
HRP20080608T3 (en)	2008-12-31	Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
AR116109A1 (es)	2021-03-31	Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
AR096450A1 (es)	2015-12-30	Compuestos para la modulación de quinasas, y sus indicaciones
AR119698A2 (es)	2022-01-05	Compuesto amida n-urea sustituida derivado de aminoácido
ATE442356T1 (de)	2009-09-15	1-essigsäureindolderivate mit pgd2- antagonistischer wirkung
HRP20020317B1 (en)	2007-08-31	Pharmaceutically active compounds
ATE556058T1 (de)	2012-05-15	1-(2h)-isochinolonderivat
AR060316A1 (es)	2008-06-11	Azaindoles de utilidad como inhibidores de janus quinasas
AR081426A1 (es)	2012-08-29	Derivados de pirazol inhibidores del receptor sigma
HRP20080477T3 (en)	2008-12-31	Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors
RS52702B (en)	2013-08-30	CARBASOL UNITS AND THERAPEUTIC USE OF THE COMPOUNDS
AR049346A1 (es)	2006-07-19	3-amino-1-arilpropil-indoles como inhibidores de reabsorcion de monoaminas
AR063101A1 (es)	2008-12-30	Derivados de pirazina-2-carboxiamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento o profilaxis de enfermedades asociadas con la modulacion de receptores del cb2.
CO6220970A2 (es)	2010-11-19	Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos
DOP2006000088A (es)	2006-10-31	Compuestos utiles en terapia
CO6331462A2 (es)	2011-10-20	Compuesto de fenil pirrol o una sal farmaceuticamente aceptable del mismo con actividad activadora de la glucoquinasa
CR10034A (es)	2008-07-22	Derivados de oxadiazol
EA201100368A1 (ru)	2011-12-30	Амидные соединения, полезные в терапии
AR068115A1 (es)	2009-11-04	Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida
AR110282A1 (es)	2019-03-13	Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
RS50642B (sr)	2010-06-30	Derivati triazolopiridinilsulfanila kao inhibitori p38 map kinaze
AR115464A1 (es)	2021-01-20	Compuestos para el tratamiento, alivio o prevención de trastornos asociados con los agregados de tau
EA201690408A1 (ru)	2016-07-29	Производные этинила
CO5650235A2 (es)	2006-06-30	Derivados de imidazol
ES2439793T3 (es)	2014-01-24	Compuestos de pirimidina, su uso como inhibidores de la mTOR quinasa y de la PI3 quinasa, y su síntesis